Articles

For every 10% reduction in expected U.S. revenues, pharmaceutical innovation is expected to decline by up to 15%, finds a new Schaeffer Center analysis. Policymakers should consider whether lowering drug prices risks undermining long-term population health.

The share of stand-alone prescription drug plans using coinsurance for preferred brand name drugs surged in recent years, exposing more patients to list prices that are often artificially inflated.

Rural Americans—particularly men—are expected to live significantly shorter, less healthy lives than their urban counterparts. “Diseases of despair” are fueling this widening gap.

A two-pronged reform strategy can limit the competitive edge for Medicare Advantage plans that aggressively upcode while lowering overpayments.

Schaeffer Center research shows expanding access to breakthrough anti-obesity medications can broadly generate positive social returns while potentially shrinking health disparities.

Adding a floor price mechanism would protect valuable innovation and effectively give future generations of patients a seat at the negotiating table.

Subjecting Wegovy to price controls would crush innovation and discourage new entrants to this important new class of anti-obesity medications that could help millions of Americans.

People with substantial mental health needs appear to receive much less mental healthcare after they age into Medicare, while use of non-mental healthcare is unaffected.

Since 2012, the Schaeffer Center has received $6.1 million in funding from the NIH to fund pilot projects by junior scholars focused on addressing disparities. This year we are seeking junior scientists concentrating on Alzheimer’s disease and related dementias in minority populations.

Removing prescribing requirements and cost barriers could significantly improve access to contraception. However, successful implementation will require careful consideration of operational processes.